Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.60 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359911 | 0.81 | KDM4E (0.41) | CDK1YTHDC1CCNE1CDK2CYP1A2 | |
| SCHEMBL14566583 | 0.79 | CDK1 (0.53) | CDK1YTHDC1CCNE1CDK2CYP1A2 | |
| SCHEMBL21128173 | 0.79 | CDK1 (0.40) | CDK1YTHDC1CCNE1CDK2CYP1A2 | |
| SCHEMBL183291 | 0.79 | CDK1 (0.51) | CDK1YTHDC1CCNE1CDK2CCNE2 | |
| SCHEMBL183035 | 0.78 | CDK1 (0.68) | CDK1YTHDC1CCNE1CDK2CCNE2 | |
| SCHEMBL29426225 | 0.78 | CDK1 (0.68) | CDK1YTHDC1CCNE1CDK2CCNE2 | |
| SCHEMBL26351761 | 0.77 | CDK1 (0.38) | CDK1YTHDC1CCNE1CDK2CYP1A2 | |
| SCHEMBL12359811 | 0.77 | PDE4A (0.43) | CDK1YTHDC1CCNE1CDK2CYP1A2 | |
| SCHEMBL12375380 | 0.77 | CYP1A2 (0.42) | CDK1YTHDC1CCNE1CDK2CYP1A2 | |
| SCHEMBL25876344 | 0.77 | CDK1 (0.66) | CDK1YTHDC1CCNE1CDK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288503-A1 | Novel compounds | ADAMS JERRY L | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288503-A1 | Novel compounds | CREBBP, NCBP1, MAPKAPK2 | CDK1 282/4885YTHDC1 4038/4885CCNE1 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.